CLEC5A產(chǎn)品信息
別稱(chēng):CLEC5A,MDL1
物種:Human
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
CLEC5A分子背景
CLEC5A,也稱(chēng)為MDL1和MDL-1,是C型凝集素/C型凝集素樣結(jié)構(gòu)域(CTL/CTLD)超家族的成員。CLEC5A在單核細(xì)胞、巨噬細(xì)胞和中性粒細(xì)胞上表達(dá)。在類(lèi)風(fēng)濕性關(guān)節(jié)炎中,其在單核細(xì)胞上的表達(dá)上調(diào)。CLEC5A與dnax活化蛋白12結(jié)合,可能在細(xì)胞活化中發(fā)揮作用。它還具有破骨細(xì)胞生成的積極調(diào)節(jié)作用。CLEC5A是自身免疫性關(guān)節(jié)炎癥期間滑膜損傷和骨侵蝕的關(guān)鍵調(diào)節(jié)因子。登革熱病毒與CLEC5A的結(jié)合通過(guò)TYROBP的磷酸化觸發(fā)信號(hào)傳導(dǎo),這種相互作用不會(huì)導(dǎo)致病毒進(jìn)入,但會(huì)刺激促炎細(xì)胞因子的釋放。
關(guān)鍵字: CLEC5A;CLEC5A蛋白;CLEC5A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。